INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company s ongoing vaccine developments for COVID-19.
A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.
Share this article
Share this article
PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA), will discontinue funding for the Phase 3 segment of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 segment. In correspondence, JPEO informed INOVIO: The decision results from the changing environment of
10 Best Biotech Stocks Under $6 in 2021
The global biotechnology sector is expected to grow to more than $2.5 trillion by the end of this decade. The growth in the industry is expected to be driven by innovation, research, and new scientific discoveries. There is plenty of reason to be hopeful about the future of biotechnology, one of the core ones being the performance of the sector in 2020, a year ravaged by the worst pandemic in more than hundred years that took the lives of millions across the world. Even through the grim twelve months, the biotech sector exceeded market expectations.
In 2020, even as most biotech firms dedicated a large part of the year to finding a cure for the coronavirus, there were 53 new medicines approved by the US drug agency. This was the second-highest number of medicines approved in a single year. Some of the notable mentions in the new medicine list include Danyelza, a drug for pediatric neuroblastoma, developed by Y-mAbs Therapeutics, Inc. (NASDA
CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa ghanavisions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanavisions.com Daily Mail and Mail on Sunday newspapers.
INOVIO to Present at Upcoming Investor Conferences in March
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and CEO, along with other members of INOVIO management, will present at the following investor conferences in March:
H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9, 2021
Virtual 1x1 meetings only
Date: Thursday, March 18, 2021
Time: 10:40 a.m. ET
Presentation Format: Corporate Presentation